Chi KN - Search Results

1

Optimal sequencing of enzalutamide and abiraterone acetate plus prednisone in metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase 2, crossover trial.

Khalaf DJ, Annala M, Taavitsainen S, Finch DL, Oja C, Vergidis J, Zulfiqar M, Sunderland K, Azad AA, Kollmannsberger CK, Eigl BJ, Noonan K, Wadhwa D, Attwell A, Keith B, Ellard SL, Le L, Gleave ME, Wyatt AW, Chi KN. Khalaf DJ, et al. Among authors: chi kn. Lancet Oncol. 2019 Dec;20(12):1730-1739. doi: 10.1016/S1470-2045(19)30688-6. Epub 2019 Nov 11. Lancet Oncol. 2019. PMID: 31727538 Clinical Trial.

2

Carboplatin and vinblastine for the treatment of metastatic transitional cell carcinoma of the urothelial tract.

Al-Karim HA, Tan KE, Chi KN, Bryce CJ, Murray NR, Coppin C. Al-Karim HA, et al. Among authors: chi kn. Am J Clin Oncol. 2002 Oct;25(5):515-9. doi: 10.1097/00000421-200210000-00019. Am J Clin Oncol. 2002. PMID: 12393996

3

Randomized, double-blind, controlled trial of mitoxantrone/prednisone and clodronate versus mitoxantrone/prednisone and placebo in patients with hormone-refractory prostate cancer and pain.

Ernst DS, Tannock IF, Winquist EW, Venner PM, Reyno L, Moore MJ, Chi K, Ding K, Elliott C, Parulekar W. Ernst DS, et al. J Clin Oncol. 2003 Sep 1;21(17):3335-42. doi: 10.1200/JCO.2003.03.042. J Clin Oncol. 2003. PMID: 12947070 Clinical Trial.

4

Antisense approaches in prostate cancer.

Chi KN, Gleave ME. Chi KN, et al. Expert Opin Biol Ther. 2004 Jun;4(6):927-36. doi: 10.1517/14712598.4.6.927. Expert Opin Biol Ther. 2004. PMID: 15174974 Review.

5

Timing is everything: preclinical evidence supporting simultaneous rather than sequential chemohormonal therapy for prostate cancer.

Eigl BJ, Eggener SE, Baybik J, Ettinger S, Chi KN, Nelson C, Wang Z, Gleave ME. Eigl BJ, et al. Among authors: chi kn. Clin Cancer Res. 2005 Jul 1;11(13):4905-11. doi: 10.1158/1078-0432.CCR-04-2140. Clin Cancer Res. 2005. PMID: 16000589 Free article.

6

A phase I pharmacokinetic and pharmacodynamic study of OGX-011, a 2'-methoxyethyl antisense oligonucleotide to clusterin, in patients with localized prostate cancer.

Chi KN, Eisenhauer E, Fazli L, Jones EC, Goldenberg SL, Powers J, Tu D, Gleave ME. Chi KN, et al. J Natl Cancer Inst. 2005 Sep 7;97(17):1287-96. doi: 10.1093/jnci/dji252. J Natl Cancer Inst. 2005. PMID: 16145049 Clinical Trial.

7

Minimizing treatment without compromising cure with primary surveillance for clinical stage I embryonal predominant nonseminomatous testicular cancer: a population based analysis from British Columbia.

Al-Tourah AJ, Murray N, Coppin C, Kollmannsberger C, Man A, Chi KN. Al-Tourah AJ, et al. Among authors: chi kn. J Urol. 2005 Dec;174(6):2209-13, discussion 2213. doi: 10.1097/01.ju.0000181810.22617.f8. J Urol. 2005. PMID: 16280765

8

Knock-down of the cytoprotective gene, clusterin, to enhance hormone and chemosensitivity in prostate and other cancers.

Gleave M, Chi KN. Gleave M, et al. Among authors: chi kn. Ann N Y Acad Sci. 2005 Nov;1058:1-15. doi: 10.1196/annals.1359.001. Ann N Y Acad Sci. 2005. PMID: 16394121 Review.

9

A phase I dose finding study of cisplatin, gemcitabine, and weekly docetaxel for patients with advanced transitional cell cancer.

Tinker A, Winquist E, Canil C, Moore M, Murray RN, Chi KN. Tinker A, et al. Among authors: chi kn. Am J Clin Oncol. 2006 Feb;29(1):3-7. doi: 10.1097/01.coc.0000200044.81711.57. Am J Clin Oncol. 2006. PMID: 16462494 Clinical Trial.

10

Prednisone monotherapy in asymptomatic hormone refractory prostate cancer.

Heng DY, Chi KN. Heng DY, et al. Among authors: chi kn. Can J Urol. 2006 Dec;13(6):3335-9. Can J Urol. 2006. PMID: 17187697

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

269 results

Search Page